Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2016
At a glance
- Drugs Rucaparib (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms RIO
- 19 Dec 2016 Status changed to active, no longer recruiting.
- 11 Oct 2016 Recruitment is expected to complete early 2017, as per the trial design presented at 41st European Society for Medical Oncology Congress.
- 11 Oct 2016 Trial design presented at 41st European Society for Medical Oncology Congress.